Retina Regeneration Therapy (Ellex 2RT™) is a research project aimed at developing a non-damaging laser treatment that stimulates the retinal pigment epithelium (RPE) to preserve vision. As a possible therapy for early age-related macular degeneration (AMD) and other retinal diseases, Ellex 2RT™ aims to treat the cause of the disease, before vision loss occurs.
If successful, Ellex 2RT™ will significantly improve the quality of life of millions of elderly people and reduce health care expenditure worldwide.
Initial laboratory studies successfully demonstrated that Ellex 2RT™ can be used to influence the early cause of AMD by triggering a cell regeneration process to improve the transport properties of Bruch’s membrane and thereby partially reverse the degradation that could lead to Wet or Dry AMD. Further laboratory studies measuring the hydroconductivity of Bruch’s membrane have also shown that Ellex 2RT™ rejuvenates the whole transport mechanism of the retina. Clinical trials are currently underway to validate the efficacy of Ellex 2RT™ for a number of clinical indications, the most important of which is AMD, and we look forward to updating you on our progress.
Download Center
Ellex 2RT in the Media
CAN EARLY LASER THERAPY DELAY DISEASE PROGRESSION?Retinal Physician, September, 2009 |
ELLEX LOOKS TO LASER RETINA REGENERATION THERAPY AS FUTURE FOR TREATING MACULOPATHY AND AMDEuroTimes, January, 2009 |
STUDY SHOWS ELLEX 2RT SAFE, EFFECTIVE FOR TREATING DIABETIC MACULAR EDEMAOSN SuperSite, November, 2008 |
LASER TREATMENT SHOWS PROMISE FOR DIABETIC MACULAR EDEMARetina Today, July/August 2008 |
NEW LASER THERAPY QUICKLY HALTS DIABETIC MACULOPATHY: 2RT TREATS DISEASE EARLY & LEAVES PHOTORECEPTORS UNHARMEDOphthalmology Times Europe, April 2008 |
USING LASER THERAPY FOR DIABETIC MACULOPATHY AND AMDOphthalmology Times, November 2007 |
IRV ARONS' JOURNALIrving Arons spent more than 30 years as a consultant to the ophthalmology industry, and more than 20 years as a medical laser industry consultant before retiring in 2005. Since then, he has continued to follow and comment on notable industry research, events and other topics in his blog, “Irv Aron’s Journal.” Late in 2007, he included a lengthy entry about 2RT research, writing, in part, “In looking further into this technique, I became convinced that, although it was very early in its development, it held the potential to become an important treatment in the armamentarium of retinal physicians." |
Press Releases
13 NOV 2009
|
10 NOV 2008
|
10 NOV 2007
|
1 NOV 2007
|
Presentations
WEBINARS
"Photoregeneration" - Tissue Interaction and Mechanisms of Action Professor Marshall will explain the mechanisms of action behind Selective Laser Trabeculoplasty and their relationship to emerging non-thermal therapies for restoring retinal function. |
